SoylentNews

The FDA has completed the environmental review for a proposed field trial to determine whether the release of Oxitec Ltd.'s genetically engineered (GE) mosquitoes (OX513A) will suppress the local Aedes aegypti mosquito population in the release area at Key Haven, Florida. After considering thousands of public comments, the FDA has published a final environmental assessment (EA) and finding of no significant impact (FONSI) that agrees with the EA's conclusion that the proposed field trial will not have significant impacts on the environment.

[The genetically engineered mosquitoes possess a] self-limiting gene that prevents the offspring from surviving. Male modified mosquitoes, which do not bite or spread disease, are released to mate with the pest females. Their offspring inherit the self-limiting gene and die before reaching adulthood—before they can reproduce or spread disease.

[Release of the OX513A mosquitoes in both Brazil and the Cayman Islands] strongly suppressed the target wild population—by 80–95%